Douglas S. Ingram's most recent trade in Relay Therapeutics Inc was a trade of 32,947 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relay Therapeutics Inc | Douglas S. Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2026 | 32,947 | 32,947 | - | - | Stock Option (Right to Buy) | |
| Arrowhead Pharma Inc | Mr. Douglas S. Ingram,Esq. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2025 | 7,819 | 46,215 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Douglas S. Ingram | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2025 | 269,542 | 929,391 (1%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Douglas S. Ingram | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2025 | 96,541 | 659,849 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Douglas S. Ingram | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2025 | 73,001 | 563,308 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Douglas S. Ingram | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2025 | 50,000 | 490,307 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Douglas S. Ingram | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2025 | 50,000 | 440,307 (0%) | 0% | 0 | Common Stock | |
| Relay Therapeutics Inc | Douglas S. Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 136,681 | 136,681 | - | - | Stock Option (Right to Buy) | |
| Arrowhead Pharma Inc | Mr. Douglas S. Ingram,Esq. | Director | Grant, award, or other acquisition of securities at price $ 20.09 per share. | 06 Feb 2025 | 38,396 | 38,396 (0%) | 0% | 20.1 | 771,376 | Common Stock |
| Relay Therapeutics Inc | Douglas S. Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 102,225 | 102,225 | - | - | Stock Option (Right to Buy) | |
| Relay Therapeutics Inc | Douglas S. Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 66,055 | 66,055 | - | - | Stock Option (Right to Buy) | |
| Relay Therapeutics Inc | Douglas S. Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 41,597 | 41,597 | - | - | Stock Option (Right to Buy) | |
| Sarepta Therapeutics Inc | Douglas S. Ingram | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 79.94 per share. | 17 Nov 2021 | 25,026 | 365,082 (0%) | 0% | 79.9 | 2,000,578 | Common Stock |